Alembic Pharma

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE901L01018
NSEID: APLLTD
BSEID: 533573

INR

858.70

9.8 (1.15%)

BSENSE

Dec 19

BSE+NSE Vol: 71.98 k

{
  "main_header": {
    "sid": 807696,
    "name": "Alembic Pharma",
    "stock_name": "Alembic Pharma",
    "full_name": "Alembic Pharmaceuticals Ltd.",
    "name_url": "stocks-analysis/alembic-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "858.70",
    "chg": 9.8,
    "chgp": "1.15%",
    "dir": 1,
    "prev_price": "848.90",
    "mcapval": "16,791.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 533573,
    "symbol": "APLLTD",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE901L01018",
    "curr_date": "Dec 19",
    "curr_time": "",
    "bse_nse_vol": "71.98 k",
    "exc_status": "Active",
    "traded_date": "Dec 19, 2025",
    "traded_date_str": "2025 12 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/alembic-pharma-807696-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Alembic Pharma Sees Revision in Market Assessment Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharma-downgraded-to-sell-by-marketsmojo-amid-weak-financial-trends-3761135",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AlembicPharma_mojoScore_3761135.png",
        "date": "2025-12-17 10:10:32",
        "description": "Alembic Pharma, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a more cautious outlook. This shift follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, set against a backdrop of subdued stock performance and sector dynamics."
      },
      {
        "title": "Why is Alembic Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-alembic-pharma-fallingrising-3759131",
        "imagepath": "",
        "date": "2025-12-16 00:47:01",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Performance and Market Comparison</strong></p>\n<p>Over the past week, Alembic Pharma’s stock has fallen by 1.94%, contrasting sharply with the Sensex’s modest gain of 0.13%. This negative momentum extends over longer periods, with the stock declining 4.35% in the last month while the benchmark rose 0.77%. Year-to-date figures reveal a more pronounced divergence: Alembic Pharma has lost 18.47% of its value, whereas the Sensex has advanced by 9.05%. Over the last year, the stock’s return stands at -18.74%, significantly underperforming the Sensex’s 3.75% gain. Even over three years, despite a positive 47.32% return, Alembic Pharma only marginally outpaced the Sensex’s 37.89%, and its five-year performance remains disappointing with a 19.72% loss compared to the Sensex’s robust 84...."
      },
      {
        "title": "Alembic Pharmaceuticals: Technical Momentum Shifts Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-faces-bearish-momentum-amid-technical-downgrade-3740237",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AlembicPharmace_technicaldot_3740237.png",
        "date": "2025-12-02 08:08:59",
        "description": "Alembic Pharmaceuticals is currently navigating a phase marked by a discernible shift in technical momentum, reflecting evolving market dynamics within the Pharmaceuticals & Biotechnology sector. Recent assessment changes highlight a transition in key technical indicators, signalling a more cautious outlook for the stock amid broader market fluctuations."
      },
      {
        "title": "Alembic Pharmaceuticals: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharmaceuticals-downgraded-to-sell-amid-technical-weakness-and-growth-concerns-3730418",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AlembicPharmace_mojoScore_3730418.png",
        "date": "2025-11-26 08:18:57",
        "description": "Alembic Pharmaceuticals has experienced a revision in its market assessment following a detailed review of its financial performance, valuation metrics, and technical indicators. The pharmaceutical company’s recent quarterly results, long-term growth trends, and evolving technical signals have collectively influenced the updated evaluation of its investment profile."
      },
      {
        "title": "Alembic Pharmaceuticals: Technical Momentum Shifts Signal Market Caution",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-faces-mildly-bearish-momentum-amid-technical-downgrade-3730303",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AlembicPharmace_technicaldot_3730303.png",
        "date": "2025-11-26 08:07:05",
        "description": "Alembic Pharmaceuticals has experienced a notable shift in its technical momentum, with recent evaluation adjustments indicating a transition from a sideways trend to a mildly bearish stance. This development is underscored by mixed signals from key technical indicators such as MACD, RSI, moving averages, and volume-based metrics, suggesting a nuanced market outlook for the pharmaceutical sector player."
      },
      {
        "title": "How has been the historical performance of Alembic Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-alembic-pharma-3729609",
        "imagepath": "",
        "date": "2025-11-25 22:56:06",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profit Trends</strong></p>\n<p>Over the seven-year period ending March 2025, Alembic Pharma’s net sales have shown consistent growth, increasing from ₹3,935 crores in 2019 to ₹6,672 crores in 2025. This represents a compound annual growth rate (CAGR) of approximately 10.5%, reflecting the company’s expanding market presence and product portfolio. Total operating income mirrors this trend, as other operating income remained nil throughout the period.</p>\n<p>Operating profit before depreciation and interest (PBDIT) excluding other income exhibited volatility, peaking at ₹1,480 crores in 2021 before moderating to ₹1,008 crores in 2025. The operating profit margin (excluding other income) declined from a high of 27.45% in 2021 to 15.11% in 2025, indicating rising costs or pricing pres..."
      },
      {
        "title": "Alembic Pharmaceuticals Forms Death Cross Signalling Potential Bearish Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-forms-death-cross-signalling-potential-bearish-trend-3729502",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AlembicPharmace_dealthcross_3729502.png",
        "date": "2025-11-25 18:20:21",
        "description": "Alembic Pharmaceuticals has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average. This development is often interpreted as a signal of weakening momentum and potential long-term bearishness for the stock, raising concerns among investors about the company’s near-term trend."
      },
      {
        "title": "Alembic Pharmaceuticals Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-technical-momentum-shifts-amid-mixed-market-signals-3727568",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AlembicPharmace_technicaldot_3727568.png",
        "date": "2025-11-25 08:10:24",
        "description": "Alembic Pharmaceuticals has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend. This change reflects a complex interplay of technical indicators, including MACD, RSI, moving averages, and volume-based metrics, which together paint a nuanced picture of the stock’s near-term market behaviour."
      },
      {
        "title": "Is Alembic Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-alembic-pharma-technically-bullish-or-bearish-3713916",
        "imagepath": "",
        "date": "2025-11-19 08:15:51",
        "description": "As of 18 November 2025, the technical trend for Alembic Pharma has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, supported by the weekly MACD and KST both indicating bearish signals, along with the Dow Theory and Bollinger Bands also showing mildly bearish trends. The daily moving averages are mildly bullish, but this is outweighed by the overall bearish indicators in the weekly and monthly time frames. The stock has underperformed against the Sensex in various time frames, further reinforcing the bearish outlook...."
      }
    ],
    "total": 5254,
    "sid": "807696",
    "stock_news_url": "https://www.marketsmojo.com/news/alembic-pharmaceuticals-807696"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "18-Dec-2025",
      "details": "Alembic Pharmaceuticals Limited announces USFDA approval for Travoprost Ophthalmic Solutions",
      "source": "BSE"
    },
    {
      "caption": "Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "16-Dec-2025",
      "details": "Please find attached herewith announcement under Regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "15-Dec-2025",
      "details": "Please find attached Newspaper Publication of Special Window for re-lodgement of transfer of physical shares.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Alembic Pharmaceuticals Ltd. has declared <strong>550%</strong> dividend, ex-date: 29 Jul 25",
          "dt": "2025-07-29",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Alembic Pharma Sees Revision in Market Assessment Amid Mixed Financial Signals

2025-12-17 10:10:32

Alembic Pharma, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a more cautious outlook. This shift follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, set against a backdrop of subdued stock performance and sector dynamics.

Why is Alembic Pharma falling/rising?

2025-12-16 00:47:01

Recent Price Performance and Market Comparison

Over the past week, Alembic Pharma’s stock has fallen by 1.94%, contrasting sharply with the Sensex’s modest gain of 0.13%. This negative momentum extends over longer periods, with the stock declining 4.35% in the last month while the benchmark rose 0.77%. Year-to-date figures reveal a more pronounced divergence: Alembic Pharma has lost 18.47% of its value, whereas the Sensex has advanced by 9.05%. Over the last year, the stock’s return stands at -18.74%, significantly underperforming the Sensex’s 3.75% gain. Even over three years, despite a positive 47.32% return, Alembic Pharma only marginally outpaced the Sensex’s 37.89%, and its five-year performance remains disappointing with a 19.72% loss compared to the Sensex’s robust 84....

Alembic Pharmaceuticals: Technical Momentum Shifts Amid Market Challenges

2025-12-02 08:08:59

Alembic Pharmaceuticals is currently navigating a phase marked by a discernible shift in technical momentum, reflecting evolving market dynamics within the Pharmaceuticals & Biotechnology sector. Recent assessment changes highlight a transition in key technical indicators, signalling a more cautious outlook for the stock amid broader market fluctuations.

Alembic Pharmaceuticals: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals

2025-11-26 08:18:57

Alembic Pharmaceuticals has experienced a revision in its market assessment following a detailed review of its financial performance, valuation metrics, and technical indicators. The pharmaceutical company’s recent quarterly results, long-term growth trends, and evolving technical signals have collectively influenced the updated evaluation of its investment profile.

Alembic Pharmaceuticals: Technical Momentum Shifts Signal Market Caution

2025-11-26 08:07:05

Alembic Pharmaceuticals has experienced a notable shift in its technical momentum, with recent evaluation adjustments indicating a transition from a sideways trend to a mildly bearish stance. This development is underscored by mixed signals from key technical indicators such as MACD, RSI, moving averages, and volume-based metrics, suggesting a nuanced market outlook for the pharmaceutical sector player.

How has been the historical performance of Alembic Pharma?

2025-11-25 22:56:06

Revenue and Profit Trends

Over the seven-year period ending March 2025, Alembic Pharma’s net sales have shown consistent growth, increasing from ₹3,935 crores in 2019 to ₹6,672 crores in 2025. This represents a compound annual growth rate (CAGR) of approximately 10.5%, reflecting the company’s expanding market presence and product portfolio. Total operating income mirrors this trend, as other operating income remained nil throughout the period.

Operating profit before depreciation and interest (PBDIT) excluding other income exhibited volatility, peaking at ₹1,480 crores in 2021 before moderating to ₹1,008 crores in 2025. The operating profit margin (excluding other income) declined from a high of 27.45% in 2021 to 15.11% in 2025, indicating rising costs or pricing pres...

Alembic Pharmaceuticals Forms Death Cross Signalling Potential Bearish Trend

2025-11-25 18:20:21

Alembic Pharmaceuticals has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average. This development is often interpreted as a signal of weakening momentum and potential long-term bearishness for the stock, raising concerns among investors about the company’s near-term trend.

Alembic Pharmaceuticals Technical Momentum Shifts Amid Mixed Market Signals

2025-11-25 08:10:24

Alembic Pharmaceuticals has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend. This change reflects a complex interplay of technical indicators, including MACD, RSI, moving averages, and volume-based metrics, which together paint a nuanced picture of the stock’s near-term market behaviour.

Is Alembic Pharma technically bullish or bearish?

2025-11-19 08:15:51

As of 18 November 2025, the technical trend for Alembic Pharma has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, supported by the weekly MACD and KST both indicating bearish signals, along with the Dow Theory and Bollinger Bands also showing mildly bearish trends. The daily moving averages are mildly bullish, but this is outweighed by the overall bearish indicators in the weekly and monthly time frames. The stock has underperformed against the Sensex in various time frames, further reinforcing the bearish outlook....

View All News